CVS Health Corporation $CVS Stock: Focused Alpha LLC Lowers Position

Focused Alpha LLC trimmed its stake in shares of CVS Health Corporation (NYSE:CVS) by 52.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,087 shares of the pharmacy operator’s stock after selling 6,836 shares during the period. Focused Alpha LLC’s holdings in CVS Health were worth $522,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in CVS Health in the 2nd quarter worth approximately $12,747,462,000. State Street Corp lifted its stake in shares of CVS Health by 26.3% in the 2nd quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator’s stock valued at $7,751,205,000 after purchasing an additional 15,604,883 shares during the period. Wellington Management Group LLP lifted its stake in shares of CVS Health by 49.8% in the 2nd quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator’s stock valued at $3,496,725,000 after purchasing an additional 11,233,381 shares during the period. Bank of America Corp DE grew its position in CVS Health by 148.0% during the second quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock valued at $2,398,868,000 after buying an additional 13,836,701 shares during the period. Finally, Pzena Investment Management LLC acquired a new stake in CVS Health during the second quarter valued at $1,217,558,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Stock Performance

NYSE:CVS opened at $92.68 on Tuesday. The company’s 50-day moving average price is $91.68 and its 200-day moving average price is $93.33. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The company has a market cap of $118.53 billion, a P/E ratio of 11.78, a P/E/G ratio of 0.86 and a beta of 0.60. CVS Health Corporation has a twelve month low of $69.51 and a twelve month high of $110.68.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. During the same quarter in the prior year, the company earned $1.81 EPS. CVS Health’s revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, sell-side analysts forecast that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd will be issued a $0.6650 dividend. This represents a $2.66 annualized dividend and a yield of 2.9%. The ex-dividend date is Thursday, October 22nd. CVS Health’s dividend payout ratio is presently 70.37%.

Analysts Set New Price Targets

Several research firms have recently issued reports on CVS. Truist Financial increased their target price on shares of CVS Health from $108.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. JPMorgan Chase & Co. upped their price target on CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Royal Bank Of Canada increased their price target on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research report on Thursday, July 9th. BMO Capital Markets set a $112.00 price objective on CVS Health in a report on Wednesday, September 9th. Finally, Wells Fargo & Company boosted their price objective on CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Twenty investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $107.80.

CVS Health Profile

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.